Showing results (1-10 of 22) with videos related to
Sort By:
Pageof 3
Therapeutic Advances in Drug Safety|June 18, 2019
Effectiveness of the golimumab educational program in ensuring healthcare professionals' awareness of risks described in the European risk management planLauren Felo, Marijo Otero-Lobato, Anja Geldhof, et al.Trends in Parasitology|March 24, 2004
Alternatively activated macrophages during parasite infectionsWim Noël, Geert Raes, Gholamreza Hassanzadeh Ghassabeh, et al.Journal of Leukocyte Biology|April 3, 2002
Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophagesGeert Raes, Patrick De Baetselier, Wim Noël, et al.Clinical & Developmental Immunology|February 11, 2004
Ablation of NK cell function during tumor growth favors Type 2-associated macrophages, leading to suppressed CTL generationAnja B Geldhof, Jo A van Ginderachter, Yuanqing Liu, et al.Developmental Immunology|August 2, 2003
FIZZ1 and Ym as tools to discriminate between differentially activated macrophagesGeert Raes, Wim Noël, Alain Beschin, et al.Blood|October 24, 2002
Antagonistic effect of NK cells on alternatively activated monocytes: a contribution of NK cells to CTL generationAnja B Geldhof, Jo A Van Ginderachter, YuanQing Liu, et al.Journal of Pharmaceutical Health Care and Sciences|May 5, 2022
Risk Management Plans: reassessment of safety concerns based on Good Pharmacovigilance Practices Module V (Revision 2)-a company experienceSuzan Esslinger, Linda Quinn, Sami Sampat, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 10, 2005
Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infectionLea Brys, Alain Beschin, Geert Raes, et al.Infection and Immunity|October 16, 2002
Infection stage-dependent modulation of macrophage activation in Trypanosoma congolense-resistant and -susceptible miceWim Noël, Gholamreza Hassanzadeh, Geert Raes, et al.Clinical Drug Investigation|August 12, 2020
Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims DatabaseNajat J Ziyadeh, Anja Geldhof, Wim Noël, et al.Pageof 3